Anonymousabout 3 hours ago
The 2026 ACC/AHA dyslipidemia guidelines, released in March 2026, set stricter LDL cholesterol targets — including a new 55 mg/dL threshold for very-high-risk patients — expand the recommended use of expensive non-statin drugs like PCSK9 inhibitors and bempedoic acid, and push for treatment earlier in life. The update has drawn praise for incorporating newer evidence but faces criticism over the writing committee's extensive pharmaceutical industry ties and concerns that aggressive pharmacological targets may overshadow lifestyle interventions, particularly for lower-risk patients who stand to gain modest absolute benefits.